European Commission Approves Nivolumab/Relatlimab Combo for Treatment of Unresectable or Metastatic Melanoma
The European Commission based its approval of nivolumab/relatlimab for patients with a PD-L1 expression of less than 1% on the results of the phase 2/3 RELATIVITY-047 trial.
A fixed-dose combination of nivolumab and relatlimab-rmbw (Opdualag) was approved by the European Commission for treating unresectable or metastatic melanoma with tumor cell PD-L1 expression of less than 1% in adults and adolescents 12 years of age and older, according to a press release from Bristol Myers Squibb.1
The regulatory decision was supported by findings from an exploratory analysis of the phase 2/3 RELATIVITY-047 trial (NCT03470922), comparing the use of nivolumab/relatlimab vs nivolumab monotherapy. According to the trial results, nivolumab and relatlimab yielded a median progression-free survival (PFS) of 10.1 months (95% CI, 6.4-15.7) compared with 4.6 months (95% CI, 3.4-5.6) in the single-agent nivolumab arm (HR, 0.75; 95% CI, 0.62-0.92; P = .0055).
“[Nivolumab with relatlimab] is now the first approved LAG-3-blocking antibody combination for advanced melanoma in the European Union,” Samit Hirawat, MD, the executive vice president and chief medical officer at Bristol Myers Squibb, said in a press release. “The RELATIVITY-047 study demonstrated the important benefit of inhibiting both LAG-3 and PD-L1 with our novel immunotherapy combination. This is a continuation of our work in bringing innovative medicines to adults and adolescents living with melanoma.”
Frequent adverse effects (AEs) included fatigue (41%), musculoskeletal pain (32%), rash (29%), and arthralgia (26%). Additionally, common serious AEs included adrenal insufficiency (1.41%), anemia (1.4%), back pain (1.1%), colitis (1.1%), and diarrhea (1.1%).
The nivolumab and relatlimab combination was previously approved by the FDA for the treatment of unresectable or metastatic melanoma in March 2022 based on findings from the phase 2/3 RELATIVITY-047 trial.2
References
- Bristol Myers Squibb receives European Commission approval for LAG-3-blocking antibody combination, Opdualag (nivolumab and relatlimab), for the treatment of unresectable or metastatic melanoma with tumor cell PD-L1 expression < 1%. News release. Bristol Myers Squibb. September 16, 2022. Accessed September 20, 2022. https://bit.ly/3drhEN1
- U.S. Food and Drug Administration approves first LAG-3-blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), as treatment for patients with unresectable or metastatic melanoma. News release. Bristol Meyers Squibb. March 18, 2022. Accessed September 22, 2022. https://bit.ly/3DNa8a4
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
